Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
货号（Catalog No.）
CS00266
通用名INN
Sirukumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Sirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
别名(Alternative names)
CNTO 136
靶点;物种(Specificity target name;species)
IL6 [Homo sapiens]
活性研究（体外/体内研究）(Activity in vitro)
Tocilizumab (anti-IL-6R) inhibits the binding of IL-6 to its receptors, and thus reduces the cytokines pro-inflammatory activity by competing for both the soluble and membrane-bound forms of the human IL-6 receptor. The inhibitory profile of anti-IL-6R mAb Tocilizumab is independent of membrane-bound IL-6R expression. Tocilizumab has anticancer potency via apoptosis induction as an agonistic IL-6R regulator. It has also been demonstrated that tocilizumab has an anti-proliferative effect on glioma cells via inhibition of the JAK-STAT3 pathway. Tocilizumab exhibits a significant growth inhibition in NSCLC cells (H460, A549, H1299 and H358), with proliferation significantly decreased by approximately 40% in A549 cells. Tocilizumab does not alter the levels of the ERK1/2, STAT3, NFκB and phosphorylated ERK1/2 and STAT3 proteins, but this antibody does considerably increase the expression of phosphorylated NFκB in NSCLC cells. Tocilizumab significantly inhibits expression of both IL-8 and MMP-9, known as the major angiogenic factors.
种类(Species)
Homo sapiens
受体鉴定(Receptor identification)
IgG1-kappa
化学信息
CAS
1194585-53-9
存储条件(Storage)
store at -80°C